02:36:00 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-02-06 Bokslutskommuniké 2024
2024-11-06 Kvartalsrapport 2024-Q3
2024-08-15 Kvartalsrapport 2024-Q2
2024-05-07 Kvartalsrapport 2024-Q1
2023-11-22 Årsstämma 2024
2023-10-13 Bonusutdelning CHR 7.72
2023-10-12 Bokslutskommuniké 2023
2023-07-06 Kvartalsrapport 2023-Q3
2023-04-13 Kvartalsrapport 2023-Q2
2023-03-30 Extra Bolagsstämma 2023
2023-01-12 Kvartalsrapport 2023-Q1
2022-11-24 Ordinarie utdelning CHR 7.04 DKK
2022-11-23 Årsstämma 2023
2022-10-12 Bokslutskommuniké 2022
2022-07-07 Kvartalsrapport 2022-Q3
2022-04-06 Kvartalsrapport 2022-Q2
2022-01-13 Kvartalsrapport 2022-Q1
2021-11-25 Ordinarie utdelning CHR 6.54 DKK
2021-11-24 Årsstämma 2022
2021-10-14 Bokslutskommuniké 2021
2021-07-08 Kvartalsrapport 2021-Q3
2021-05-18 Bonusutdelning CHR 6.54
2021-04-15 Kvartalsrapport 2021-Q2
2021-01-14 Kvartalsrapport 2021-Q1
2020-11-26 Ordinarie utdelning CHR 0.00 DKK
2020-11-25 Årsstämma 2021
2020-10-08 Bokslutskommuniké 2020
2020-07-02 Kvartalsrapport 2020-Q3
2020-04-16 Kvartalsrapport 2020-Q2
2020-01-15 Kvartalsrapport 2020-Q1
2019-11-28 Ordinarie utdelning CHR 7.07 DKK
2019-11-27 Årsstämma 2020
2019-10-10 Bokslutskommuniké 2019
2019-07-03 Kvartalsrapport 2019-Q3
2019-04-03 Kvartalsrapport 2019-Q2
2019-01-17 Kvartalsrapport 2019-Q1
2018-11-30 Ordinarie utdelning CHR 6.47 DKK
2018-11-29 Årsstämma 2019
2018-10-15 Bokslutskommuniké 2018
2018-06-29 Bonusutdelning CHR 5.94
2018-06-28 Kvartalsrapport 2018-Q3
2018-04-11 Kvartalsrapport 2018-Q2
2018-01-12 Kvartalsrapport 2018-Q1
2017-11-29 Ordinarie utdelning CHR 6.33 DKK
2017-11-29 Årsstämma 2018
2017-11-28 Årsstämma 2018
2017-10-25 Bokslutskommuniké 2017
2017-07-11 Bonusutdelning CHR 5.64
2017-07-05 Kvartalsrapport 2017-Q3
2017-04-06 Kvartalsrapport 2017-Q2
2017-01-11 Kvartalsrapport 2017-Q1
2016-11-30 Ordinarie utdelning CHR 5.23 DKK
2016-11-29 Årsstämma 2017
2016-10-26 Bokslutskommuniké 2016
2016-07-05 Kvartalsrapport 2016-Q3
2016-04-07 Kvartalsrapport 2016-Q2
2016-01-14 Kvartalsrapport 2016-Q1
2015-11-27 Ordinarie utdelning CHR 4.70 DKK
2015-11-26 Årsstämma 2016
2015-10-21 Bokslutskommuniké 2015
2015-07-07 Bonusutdelning CHR 6.57
2015-07-01 Kvartalsrapport 2015-Q3
2015-04-09 Kvartalsrapport 2015-Q2
2015-01-21 Kvartalsrapport 2015-Q1
2014-11-28 Ordinarie utdelning CHR 3.77 DKK
2014-11-27 Årsstämma 2015
2014-10-22 Bokslutskommuniké 2014
2014-07-02 Kvartalsrapport 2014-Q3
2014-04-09 Kvartalsrapport 2014-Q2
2014-01-15 Kvartalsrapport 2014-Q1
2013-11-27 Bonusutdelning CHR 3.13
2013-11-27 Ordinarie utdelning CHR 3.13 DKK
2013-11-26 Årsstämma 2014
2013-10-23 Bokslutskommuniké 2013
2013-07-03 Kvartalsrapport 2013-Q3
2013-04-11 Kvartalsrapport 2013-Q2
2013-01-16 Kvartalsrapport 2013-Q1
2012-11-28 Ordinarie utdelning CHR 2.90 DKK
2012-11-27 Årsstämma 2013
2012-07-04 Kvartalsrapport 2012-Q3
2012-04-19 Kvartalsrapport 2012-Q2
2012-01-11 Kvartalsrapport 2012-Q1
2011-11-30 Ordinarie utdelning CHR 3.57 DKK
2011-11-29 Årsstämma 2012
2011-07-06 Kvartalsrapport 2011-Q3
2011-04-06 Kvartalsrapport 2011-Q2
2011-01-12 Kvartalsrapport 2011-Q1
2010-12-01 Ordinarie utdelning CHR 0.64 DKK

Beskrivning

LandDanmark
ListaLarge Cap Copenhagen
SektorHälsovård
IndustriBioteknik
Christian Hansen Holding är en global livsmedelskoncern. Bolagets affärsinriktning återfinns inom utveckling av enzymer och naturliga färger som används som tillsatser inom livsmedelsindustrin. En stor del inom verksamheten innefattar forskning och utveckling av goda bakterier som tillsätts i probiotikaprodukter. Bolaget grundades ursprungligen 1874 och har sitt huvudkontor i Hørsholm.
2021-04-15 08:01:43

Continued strong organic growth momentum leads to upwards narrowing of full-year organic growth guidance  

  • Q2 2020/21 organic sales growth was 10%, equally split between volume/mix and price, and driven by Health & Nutrition which delivered 14% growth while Food Cultures & Enzymes delivered 8% growth
  • Underlying EBIT margin b.s.i.1) of 30.9%, incl. >1%-point negative currency impact, compared to 32.2% in Q2 2019/20. Reported EBIT margin b.s.i. (incl. all acquisition impacts) was 27.0%
  • Integration of commercial activities in UAS/HSO is completed and integration of manufacturing is progressing
  • HMO capacity expansion in Germany on track, while delays in product registrations and regulatory approvals remain a constraint on market development; the market opportunity long-term is unchanged
  • Full-year outlook for organic growth adjusted to 6-8% (previously 5-8%), free cash flow narrowed upwards to EUR 140-160 mio, EBIT margin guidance unchanged, and impacts from acquisitions also unchanged from Q1

CEO Mauricio Graber says: “In our second quarter we delivered strong organic growth on a more demanding comparable from last year, with continued good momentum in both business areas. Our business in Asia-Pacific delivered 10% organic growth
fueled by Health & Nutrition, providing reassurance that we can grow the region strongly even as the Chinese yogurt market is still in decline. Customer engagement, both in China and globally, remains high despite the current difficulties of in person interactions.

Through the acquisitions we have done, we are building a more balanced business globally between Food Cultures & Enzymes and Health & Nutrition. We’ve continued the integration of the acquired businesses and have recently completed a major milestone in the divestment of Natural Colors, and we are executing our strategy of becoming a focused bioscience company based on a unique microbial and fermentation technology platform.

Following the divestment of Natural Colors, we have initiated the process for paying out an extraordinary dividend of around EUR 116 million, and payment of the dividend is expected to be effected during the month of May.

In Q2 we progressed on our innovation agenda with many new patents, trademarks and registrations, and in Q3 we will be launching the next generation of bioprotection for fermented milks and certain cheeses.

As a result of the strong organic growth in the first half of 2020/21, and despite the uncertainties lingering from COVID-19, we have narrowed upwards our full-year outlook for organic growth, and we expect that Q4 to be the stronger of the two remaining quarters, primarily as Q3 of last year had a tailwind effect from customers building COVID-19 related safety inventories.”


Outlook for 2020/21

Organic revenue growth 6-8%

EBIT margin before special items 27-28%

Free cash flow before special items, acquisitions and divestments EUR 140-160 million


For further information, please contact:

Martin Riise, Head of IR

+45 53 39 22 50

Annika Stern, Senior IR Officer

+45 23 99 23 82


About Chr. Hansen

Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, cleaner labels and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world’s most sustainable food ingredients company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.